Executive Summary
TTVR just had its COAPT moment. TRIC-I-HF, presented at ESC 2026 and simultaneously published in NEJM, is the first randomized transcatheter tricuspid trial to move hard endpoints: a 60% relative reduction in death or HF hospitalization at 3 years (52.4% vs 21.0% event-free survival) and a 38% mortality reduction (HR 0.62) with T-TEER added to medical therapy in 360 high-risk patients. On the aortic side, two ESC late-breakers — ACASA-TAVI in JAMA and NOTION-4 in JACC — reframe post-TAVI antithrombotic strategy around leaflet thrombosis, with NOAC monotherapy cutting HALT nearly in half at 12 months versus aspirin. TRIC-I-HF tightens the case for intervening earlier in severe TR; the conflicting antithrombotic signals complicate the aspirin-only post-TAVI default that most of us have been running.
- TRIC-I-HF: T-TEER cut 1-year HF hospitalization by 65% (HR 0.35) with an NNT of 4 in patients with severe/massive/torrential TR (TCTMD/NEJM).
- ACASA-TAVI (JAMA, N=360, ages 65-80): NOAC monotherapy reduced HALT to 16.2% vs 28.6% with ASA (RR 0.55) and met noninferiority for bleeding/thromboembolism/death (JAMA).
- NOTION-4: 3-month DOAC halved HALT at 3 months (12.1% vs 31.8%) but the benefit disappeared by 12 months and the DOAC arm carried more bleeding/death (8.2% vs 2.3%) (JACC).
- Benchtop hemodynamics data show even 10° of TAVR canting creates cusp-specific stasis zones — a mechanical driver of HALT that antithrombotics cannot fix (JTCVS Structural).
- A TAVI-first strategy was noninferior to PCI-first in patients with concomitant severe AS and CAD (News-Medical, ESC 2026).
What to watch: ESC/EACTS committee response to TRIC-I-HF — whether the current Class IIa transcatheter TR recommendation gets upgraded to Class I on the strength of an NEJM-published hard-endpoint trial.
Aortic Valve (TAVR/TAVI)
Two randomized antithrombotic trials at ESC 2026 rewrote the post-TAVI drug question — and pointed in different directions. [NOTABLE] ACASA-TAVI in JAMA randomized 360 patients aged 65-80 to 12 months of NOAC monotherapy versus ASA monotherapy. HALT at 1 year fell from 28.6% to 16.2% (RR 0.55, P=0.004), and the composite of VARC-3 bleeding, thromboembolism, and death met noninferiority (7.5% vs 10.6%). NOTION-4 in JACC tested a shorter 3-month DOAC course followed by SAPT: HALT dropped early (12.1% vs 31.8% at 3 months) but rebounded to 28.3% vs 32.2% by 12 months, with more bleeding/death in the DOAC arm (8.2% vs 2.3%). The signal is that duration matters, and stopping the DOAC removes the effect. Neither trial demonstrated a clinical outcome benefit from HALT reduction — the durability question remains open. Current ACC/AHA 2020 guidelines still favor SAPT after TAVI without an anticoagulation indication, and neither trial is large enough to move that recommendation on hard endpoints alone. Meanwhile, JTCVS Structural benchtop work (patient-derived model, small-scale, not an in vivo outcome study) shows that 10° of noncoaxial valve deployment collapses sinus washout in the constrained cusp — 92% low-velocity area versus 10% in along-curvature, with T90 washout extending to 4.7 cycles versus 1.8 — and localizes thrombus histologically to the poorly washed regions. HALT carries a deployment-geometry component that pharmacology alone cannot address. SAVR with contemporary bioprostheses does not carry a routine HALT surveillance burden; the ESC 2025 age-70 TAVI threshold remains predicated on assumed durability that ongoing leaflet thrombosis findings continue to interrogate.
Mitral Valve (MitraClip, PASCAL, TMVR)
No new mitral-specific randomized data landed today. The TRIC-I-HF investigators explicitly framed their trial as a "COAPT-like moment," acknowledging that transcatheter mitral repair set the template — enrich for high HF risk, define proportionate regurgitation, insist on experienced centers. For mitral practice, the standing ESC 2025 Class I upgrade for TEER in ventricular secondary MR (based on COAPT + RESHAPE-HF2) remains the highest-grade recommendation for any transcatheter valve therapy, while ACC/AHA 2020 remains at Class IIa — a gap the next US update will need to close. The surgical counterpoint for primary MR is unchanged: mitral repair at experienced centers remains Class I in both guideline sets, and the ESC 2025 expansion of Class I early surgery to asymptomatic patients with three of four risk features (AF, pulmonary hypertension, LA dilation, TR) still outpaces ACC/AHA on aggressiveness of referral.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] TRIC-I-HF, published simultaneously in NEJM, is the first randomized transcatheter tricuspid trial to move mortality and HF hospitalization. Across 360 patients at 29 high-volume German centers (mean age 80, 75% NYHA III-IV, 55% prior HF hospitalization, 45% massive/torrential TR), T-TEER added to medical therapy delivered a win ratio of 2.42 for the hierarchical primary endpoint and reduced the composite of death or HF hospitalization by 60% at 3 years. Individual endpoints: 38% relative reduction in all-cause death (HR 0.62), 65% reduction in HF hospitalization at 1 year (HR 0.35), NNT of 4. Devices split roughly two-thirds Pascal, one-third TriClip; 62% of patients received two devices. ESC 2025 already upgraded TV surgery to Class I for symptomatic severe primary TR and holds transcatheter TR at Class IIa; ACC/AHA 2020 does not address transcatheter TR at all. TRIC-I-HF is the trial that forces both to reconsider.
The difference from TRILUMINATE Pivotal and Tri.Fr — which both showed QoL wins without hard-endpoint benefit — is aggressive enrichment for HF risk combined with operator experience at high-volume centers. Limitations to flag inline: 48 crossovers from medical therapy to TTVR (13% of the control arm, 58% during the index HF hospitalization) complicate the intention-to-treat mortality signal, and the cardiorenal/cardiohepatic burden (82%/46%) marks a population not directly generalizable to lower-acuity TR. The trial enrolled 91% secondary/functional TR — the ESC 2025 Class I surgical recommendation applies to primary TR, a largely separate population with better RV reserve and lower surgical risk. As Alkhouli put it to TCTMD: "It feels like a COAPT-like moment."
Surgical vs. Transcatheter Comparisons
No direct head-to-head randomized data landed today. TRIC-I-HF fills the evidence void that has kept isolated TV surgery in a defensive posture — the historical isolated TV surgery mortality of 8-20% is the number transcatheter proponents cite, but contemporary surgical series with earlier referral run considerably lower, and no RCT has directly compared T-TEER to isolated TV surgery in a matched population. The ESC 2025 Class I recommendation for TV surgery in symptomatic severe primary TR still stands, and TRIC-I-HF was overwhelmingly (91%) a secondary/functional TR population — a distinction that matters for surgical referral patterns. On the aortic side, the HALT question is a transcatheter-only problem. SAVR bioprostheses do not generate routine CT surveillance concerns, which remains a structural durability argument that neither ACASA-TAVI nor NOTION-4 resolves; both trials address pharmacologic mitigation of a transcatheter-specific phenomenon rather than eliminating it.
Device & Technology
Particle image velocimetry work in JTCVS Structural demonstrated that modest (10°) TAVR canting redistributes systolic jet orientation and collapses neo-sinus washout in a direction-dependent, cusp-specific manner. In the anticurvature deployment, 92% of the right coronary sinus fell below 0.05 m/s velocity (versus 10% in along-curvature), and T90 washout extended to 4.7 cycles versus 1.8. Histology localized thrombus to the poorly washed regions. This is bench model work in patient-derived anatomy — not an in vivo outcome study — but the mechanistic point is that HALT has a deployment-geometry component that pharmacology alone cannot address. Coaxial deployment discipline may matter more than the field has credited, and the HALT prevention strategies tested in ACASA-TAVI and NOTION-4 may be treating a problem partially generated by procedural technique.
Clinical Trial Updates
Beyond the three ESC late-breakers already covered, a TAVI-first vs PCI-first strategy trial reported noninferiority in patients with severe AS and concomitant CAD — practical for sequencing decisions, though full data pending peer review. Adjacent ESC signal: STAREE showed statins cut MACE by 30% in older adults without CVD history — directly relevant to the post-TAVI comorbidity profile given the age overlap. Also of interest to structural heart teams managing electrical comorbidities: a retrospective VF ablation series (N=45, 17 ICM, 28 NICM) reported 85-87% 1-year VF-free survival across both cardiomyopathy phenotypes with substrate + PVC ablation — small, single-center, not directly TAVR-relevant but useful backdrop for the frail structural heart population.
Valve Industry Stocks
Edwards Lifesciences (EW)
Closed $90.21, up 0.29% on the day, with 6-month performance of +3.48% (range $76.49-$96.29). Market cap $52.0B, trailing P/E 53.7, forward P/E 26.7, beta 0.85. Analyst consensus buy at $100.96 target (26 analysts, range $84-$110). Q3 earnings 10/29 with $0.74 EPS / $1.68B revenue estimates. Institutional activity has been busy — Jefferies added $3.58M, Kingsview and United Capital initiated or added positions, Wellington and Alyeska trimmed. TRIC-I-HF is directly relevant here: Pascal captured 65.6% of device use in the trial, making Edwards the primary commercial beneficiary if the NEJM publication drives a Class I guideline upgrade. Watch reimbursement conversations in Q4.
Medtronic (MDT)
Closed $91.23, +1.40% on the day, but -5.40% over 6 months. Market cap $116.8B, trailing P/E 24.5, forward P/E 14.2, beta 0.57. Buy consensus at $98.84 target. Earnings 9/1 with $1.39 EPS / $9.54B revenue estimates — imminent readout with structural heart segment likely in focus. Evolut Low Risk 5- and 10-year data continue to anchor the Medtronic TAVR narrative; NOTION-4's finding that HALT recurs after DOAC discontinuation reopens the durability conversation that self-expanding valve advocates have generally welcomed.
Abbott (ABT)
Closed $112.47, +0.79% daily, essentially flat over 6 months (-0.12%). Market cap $194.6B, trailing P/E 36.4, forward P/E 18.5, beta 0.58. Buy consensus at $120.20 target. Earnings 10/14 ($1.42 EPS / $12.99B revenue estimates). TriClip captured 33% of TRIC-I-HF device use — meaningful but secondary to Pascal. Abbott's structural heart business benefits from broader class effect if guidelines upgrade transcatheter TR, though Pascal's larger share of the trial may skew referral patterns near-term.
Boston Scientific (BSX)
Closed $46.84, +0.36% daily, but down 38.55% over 6 months — the sector's clear underperformer with a 52-week range of $42.20-$109.50. Market cap $67.9B, trailing P/E 19.0, forward P/E 13.6. Buy consensus at $62.69 target with a wide $44-$94 range signaling divided sentiment. Q3 earnings 10/28 ($0.81 EPS / $5.26B revenue estimates). The 6-month collapse reflects Acurate neo2 headwinds and reset expectations for the structural heart franchise; no material TAVR-specific catalyst emerged from today's ESC readouts.
Anteris Technologies (AVR.AX)
Closed A$11.97, -3.08% daily, but +36.02% over 6 months. Market cap A$1.2B. Speculative small-cap TAVR play with the DurAVR balloon-expandable single-piece bovine valve angling for a durability differentiation story. Not directly implicated in today's ESC data.
Market Outlook
The ESC 2026 late-breakers redistribute attention across the sector: Edwards is the clearest short-term winner given Pascal's dominance in TRIC-I-HF, while Boston Scientific's structural heart re-rating remains unresolved. The HALT trials (ACASA-TAVI, NOTION-4) don't move device revenue directly but reinforce a post-TAVI monitoring and pharmacologic layer that keeps imaging and DOAC utilization in the frame. Hard-endpoint transcatheter TR data changes the addressable market math for TR interventions in a way that TRILUMINATE and Tri.Fr did not.
Social & Conference Highlights
ESC 2026 in Munich dominated the feed. Rebecca Hahn's discussant slot on TRIC-I-HF framed the result as "just an incredible result" while flagging the crossover question — 48 medical therapy patients migrated to TTVR, 58% during the index HF hospitalization, which will shape substudy analyses. Mohamad Alkhouli's "COAPT-like moment" quote circulated widely on cardiology Twitter/X. Session chair Nicolas Van Mieghem explicitly called on guideline committees to revisit TR recommendations. Adjacent late-breakers pulling attention: prasugrel-by-default post-PCI in ACS reduced bleeding without ischemic penalty, relevant to structural heart teams routinely managing dual-modality patients.
What next: The immediate downstream question is whether the ESC/EACTS committee moves transcatheter TR from Class IIa to Class I on the strength of an NEJM-published hard-endpoint trial, and whether ACC/AHA — which has no current recommendation on transcatheter TR at all — accelerates its next focused update. On the aortic side, expect NOTION-4 and ACASA-TAVI to drive a real debate about default post-TAVI antithrombotic choice, with duration, bleeding phenotype, and mechanistic HALT drivers (including deployment geometry) all now on the table. Watch for the TRIC-I-HF crossover substudy and any FDA signal on TTVR labeling.